Introduction: Postoperative atrial fibrillation (POAF) is the most common complication following cardiac surgery, and randomised clinical trials (RCTs) and systematic reviews have been conducted to compare and evaluate different pharmacological interventions for preventing POAF.
. POAF normally occurs between days 2 and 4 after surgery, with maximum incidence seen on postoperative day 2, and 80% and 94% of the patients attacked by POAF do so by day 4 and by the end of day 6 respectively [7] . Furthermore, substantial impact of POAF on hospital resources was observed.
It was estimated that POAF lengthened hospital stay by 4.9 days, with an extra cost of $10,000 to $11,500 in hospital stay in the U.S [7] .
In addition to directly causing discomfort and leading to hemodynamic compromise, this complication is associated with major adverse consequences, including an increased rates of death, postoperative stroke and other complications [8] [9] [10] , hospitalizations and inflated costs [11, 12] . Contemporary studies
show that 20%-30% of patients with an ischaemic stroke have AF diagnosed before, during, or after the initial event. Cognitive impairment [13] [14] [15] , decreased quality of life [16, 17] , and depressed mood [18] are common in AF patients, and between 10-40% of AF patients are hospitalized each year [19, 20] .
Increasing researches have assessed various interventions for preventing POAF[21] based on the multifactorial etiology, including pharmacological or non-pharmacological interventions.
Pharmacologic interventions aim to reduce the dispersion of atrial refractoriness, suppress the activation of the renin-angiotensin-aldosterone system, control ectopic foci automaticity, and reduce oxidative stress and inflammation. The most commonly used pharmacologic therapies in clinical practice include beta-blockers, calcium channel blockers, amiodarone, digoxin, sotalol, magnesium [5, 22, 23] . However, there still lack consensus regarding best practices for POAF [21] management, which has contributed to major variations in practices [1, 3, 24, 25] .
Although several meta-analyses have studied various proposed prophylactic interventions for preventing POAF, they are all conducted only pairwise meta-analysis to compare efficacy of different interventions, or different durations-and doses [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Attention has been paid to developing . This study is a comprehensive NMA on different pharmacological interventions for prophylaxis against POAF after cardiac surgery.
OBJECTIVE
To comprehensively explore the effect of different pharmacological interventions for prophylaxis against postoperative atrial fibrillation after cardiac surgery using network meta-analysis.
METHODS AND ANALYSIS

Design
Bayesian NMA will be carried out in this study.
Information source
A systematic search will be performed in PubMed, EMBASE, and the Cochrane Library. Two librarians (LL and JHT) will be consulted to work on the search strategy. We will use the following search terms: atrial fibrillation, heart fibrillation, atrial fibrillation, cardiac surgery, heart surgery. No limitation of language or publication date will be set during search process. Detailed search strategy in databases are: 
Eligibility criteria
Type of patients: adult patient (≥18 years old) undergoing heart surgery, like CABG, valvular surgery, or both with no history of chronic AF.
Type of designs: randomised controlled trials (RCTs); systematic reviews, meta-analyses or NMA will be included for their references.
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Other criteria: we will include RCTs published in English. There will be no limitations on duration of study follow-up, year of publication, and publication status.
Study records
ENDNOTE X7 literature management software will be employed to screen and manage search records, while a standard data abstraction form will be developed with Microsoft Excel 2013 (Microsoft Corp, Redmond, WA). Pilot tests will be performed for literature screening and data extraction, and remarks will be made to ensure high inter-rater reliability among the reviewers.
Study eligibility will be assessed in two stages. First, pairs of reviewers will independently examine the titles and abstracts in ENDNOTE to identify related studies. Then, each full text article from the screening stage will be obtained and evaluated. Excluded trials and the reasons will be recorded and any disagreement will be resovled through discussion or consultation with an independent third adjudicator.
Data extraction
A rigorous process will be applied to extract the data. To start, the initial data extraction form will be created. Then, a random sample of three to five included RCTs will be pilot tested. If necessary, the form will be revised to complete the final data extraction. Finally, two independent reviewers willl extract the data of interest, and conflicts will be resolved through discussion or a third reviewer. The following descriptive data from eligible studies will be abstracted: country of origin, year of publication, type of surgery, interventions, treatment schema and doses, number of participants, patient characteristics, background therapies, type of surgery, outcomes measurement or monitoring, length of follow-up, definition of primary outcome and end points of AF, stroke, mortality, length of stay and cost. Any disagreement will be resolved through discussion or consultation with an independent third adjudicator.
Assessment of risk of bias of included studies
Geometry of the network
A network plot will be drawn to present the geometry of the network of comparisons across trials to ensure if a NMA is feasible. Trials will be excluded if they are not connected by interventions. Nodes in network geometry represent different interventions and edges represent the head-to-head comparisons. The size of nodes and thickness of edges are associated with sample sizes and numbers of RCTs respectively.
Pairwise meta analysis
Pairwise meta analyses will be performed using Review Manager 5.3.3 (Cochrane Collaboration, Denmark). Odds ratio (OR) with 95% confidence intervals (CI) will be used for incidence of atrial fibrillation or supraventricular tachycardia, incidence of stroke or cerebrovascular accident, and mortality rate. Mean differences (MDs) or standard mean differences (SMDs) with 95% CI for length of hospital stay, and cost of treatment during hospital stay. We will assess clinical and methodological heterogeneity through examining the characteristics of the included trials. Heterogeneity across trials will be assessed by c 2 and I 2 statistics. If the p value≥0.1 and I 2 ≤50%, which suggests there is no statistical heterogeneity, then the Mantel-Haenszel fixed effects model will be employed. If the p value <0.1 and I 2 >50%, we will explore sources of heterogeneity by subgroup analysis and meta-regression.
If no clinical heterogeneity was identified, the Mantel-Haenszel random effects model will be used [41] .
Publication bias will be examined through the Begg's and Egger's funnel plot method when applicable [42, 43] . In addition, the contour-enhanced funnel plot will be obtained as an aid to distinguish asymmetry due to publication bias [44] .
Network meta-analysis
We will perform Bayesian NMAs with package 'gemtc' version 0. will be used to examine the inconsistency between direct and indirect comparisons when a loop connecting three arms exists [47] . The ranking probabilities for all treatments will be estimated, and a treatment hierarchy using the probability of being the best treatment can be obtained. This process will be performed using the cumulative ranking curve (SUCRA) (Salanti 2011) . The SUCRA values are expressed with percentages-100% for the best treatment, while 0% for the worst treatment [48] .
Assessment of the quality of evidence
The quality of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) as four levels-high quality, moderate quality, low quality and very low quality [49] . This process will be performed with the online guideline development tool (GDT, http://gdt.guidelinedevelopment.org/).
ETHICS AND DISSEMINATION
Ethical issues
Ethical approval and patient consent are not required since this is a meta-analysis based on published studies.
Publication plan
This protocol has been registered on the international prospective register of systematic reviews (PROSPERO). The procedures of NMA will be conducted and reported according to the PRISMA extension statement for network meta-analyses. The results of this NMA and TSA will be submitted to a peer reviewed journal for publication.
Contributors
Conception and design of research (XQW, LY,
LG and KHY); tested the feasibility of the study (LL, FXL, QZ, YLC and YFW); wrote the manuscript (XQW); all the authors approved the fnal manuscript.
Competing interests
None declared. Patient consent are not required since this is a NMA based on published studies.
Sources of funding
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METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 4
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 3
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 3-4 Study records:
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Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 4
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 4
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications 4-5
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 4
Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 4
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 5 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) 5
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 5 15d If quantitative synthesis is not appropriate, describe the type of summary planned 5 Meta-bias(es)
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 5 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 6 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. cardiac surgery with network meta-analysis.
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.
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Methods and analysis: A systematic search will be performed in PubMed, EMBASE, and the
8
Cochrane Library to identify RCTs, systematic reviews, meta-analyses or NMA of different 9 pharmacological interventions for POAF. We will evaluate the risk of bias of the included RCTs 10 according to the Cochrane Handbook V.5.1.0, and use GRADE to assess the quality of evidence.
11
Standard pairwise meta-analysis, trial sequential analysis and Bayesian network meta-analysis will be 12 employed to compare the efficacy of different pharmacological interventions.
13
Ethics and dissemination: Ethical approval and patient consent are not required since this study is a 14 meta-analysis based on published studies. The results of this network meta-analysis and trial sequential 15 analysis will be submitted to a peer-reviewed journal for publication.
16
Protocol registration number: CRD42017067492
17
(https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017067492)
19
Strengths and limitations of this study
20
To the best of our knowledge, this is the first network meta-analysis to comprehensively explore 21 and compare the effect of different pharmacological interventions for prophylaxis against POAF 22 after cardiac surgery.
23
The results of this network meta-analysis will help clinicians and patients to select appropriate 24 prophylaxis methods.
25
Our results will be limited by both the quantity and quality of the trials available for this review.
27
Page 2 of 12 [6] . POAF normally occurs between days 2 and 4 after surgery, with maximum incidence seen on 5 postoperative day 2, and 80% and 94% of the patients attacked by POAF do so by day 4 and by the end 6 of day 6 respectively [7] . Furthermore, substantial impact of POAF on hospital resources was observed.
7
It was estimated that POAF lengthened hospital stay by 4.9 days, with an extra cost of $10,000 to 8 $11,500 in hospital stay in the U.S [7] .
9
In addition to directly causing discomfort and leading to hemodynamic compromise, this complication To comprehensively explore the effect of different pharmacological interventions for prophylaxis 1 against postoperative atrial fibrillation after cardiac surgery using network meta-analysis.
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METHODS AND ANALYSIS
4
Design
5
7
Information source
8
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4
Type of designs: randomized controlled trials (RCTs); systematic reviews, meta-analyses or NMA will 5 be included for their references.
6
Type of interventions: Any pharmacological intervention aimed at preventing POAF after cardiac 7 surgery.
8
Type of outcomes: the primary outcomes are incidence of AF, including in-hospital AF and AF up to 9 two week after discharge); the secondary outcomes are incidence of stroke (will be measured within 10 the same period of AF ) or cerebrovascular accident, mortality rate, length of hospital stay, cost of 11 treatment during hospital stay, adverse events. will be made to ensure high inter-rater reliability among the reviewers.
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Study eligibility will be assessed in two stages. First, pairs of reviewers will independently examine the 2 titles and abstracts in ENDNOTE to identify related studies. Then, each full text article from the 3 screening stage will be obtained and evaluated. Excluded trials and the reasons will be recorded and 4 any disagreement will be resolved through discussion or consultation with an independent third 5 adjudicator.
6
Data extraction
7
A rigorous process will be applied to extract the data. To start, the initial data extraction form will be 8 created. Then, a random sample of three to five included RCTs will be pilot tested. If necessary, the 9 form will be revised to complete the final data extraction. Finally, two independent reviewers will 10 extract the data of interest, and conflicts will be resolved through discussion or a third reviewer. The 
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Geometry of the network
25
A network plot will be drawn to present the geometry of the network of comparisons across trials to 
30
Pairwise meta analysis
31
Pairwise meta analyses will be performed using Review Manager 5.3.3 (Cochrane Collaboration, 32 Denmark). Odds ratio (OR) with 95% confidence intervals (CI) will be used for incidence of atrial 33 fibrillation or supraventricular tachycardia, incidence of stroke or cerebrovascular accident, and 34 mortality rate. Mean differences (MDs) or standard mean differences (SMDs) with 95% CI for length 35 of hospital stay, and cost of treatment during hospital stay. We will assess clinical and methodological will be used to examine the inconsistency between direct and indirect comparisons when a loop 10 connecting three arms exists [48] . The ranking probabilities for all treatments will be estimated, and a 11 treatment hierarchy using the probability of being the best treatment can be obtained. This process will 12 be performed using the cumulative ranking curve (SUCRA) (Salanti 2011 
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Assessment of the quality of evidence
16
The quality of evidence will be evaluated using the Grading of Recommendations Assessment,
17
Development and Evaluation (GRADE) as four levels-high quality, moderate quality, low quality and 18 very low quality [52] . This process will be performed with the online guideline development tool (GDT,
19
http://gdt.guidelinedevelopment.org/).
21
ETHICS AND DISSEMINATION
22
Ethical issues
23
Ethical approval and patient consent are not required since this is a meta-analysis based on published 24 studies.
25
Publication plan
26
This protocol has been registered on the international prospective register of systematic reviews 27 (PROSPERO). The procedures of NMA will be conducted and reported according to the PRISMA 28 extension statement for network meta-analyses. The results of this NMA and trial sequential analyses
29
(TSA) will be submitted to a peer reviewed journal for publication. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) 3
METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 5
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 4
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 4-5 Study records:
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Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 5
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications 6
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 5
Risk of bias in individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 6
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 6 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) 6
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 6-7 15d If quantitative synthesis is not appropriate, describe the type of summary planned 6 Meta-bias(es)
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 6 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 7 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
